Cargando…
Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines contain...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/ https://www.ncbi.nlm.nih.gov/pubmed/36974988 http://dx.doi.org/10.1080/21645515.2023.2187194 |
_version_ | 1785020450540093440 |
---|---|
author | Galgani, Ilaria Põder, Airi Jõgi, Rain Anttila, Veli-Jukka Milleri, Stefano Borobia, Alberto M. Launay, Odile Testa, Marco Casula, Daniela Grassano, Luca Tasciotti, Annaelisa Dozot, Marie Arora, Ashwani K. |
author_facet | Galgani, Ilaria Põder, Airi Jõgi, Rain Anttila, Veli-Jukka Milleri, Stefano Borobia, Alberto M. Launay, Odile Testa, Marco Casula, Daniela Grassano, Luca Tasciotti, Annaelisa Dozot, Marie Arora, Ashwani K. |
author_sort | Galgani, Ilaria |
collection | PubMed |
description | A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines containing the same AS01-adjuvant system could lead to immune interference. We compared administration of NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. This phase 2a, open-label trial (NCT03894969) randomized healthy current or former smokers (50–80 years) without COPD to administration of NTHi-Mcat at 1, 3 or 6 months after RZV or to NTHi-Mcat alone (2-dose for both vaccines). Primary outcome was non-inferiority of the humoral immune response to NTHi-Mcat administered 1 month after RZV versus NTHi-Mcat alone, evaluated by specific antibody geometric mean concentration (GMC) ratio with 95% confidence intervals (CIs). The per-protocol set included 411 participants. Primary objective was met; lower limit of the 95%CI for the GMC ratio above 0.667 for all four vaccine antigens, 1 month after the second NTHi-Mcat dose. NTHi-Mcat induced similar immune response regardless of whether administered alone or 1, 3 or 6 months following RZV. Safety and reactogenicity profiles were acceptable; adverse event frequency was similar among study groups. Injection site pain was the most common symptom. No new safety concerns were identified. The study demonstrated non-inferiority of the immune response elicited by NTHi-Mcat administered sequentially to RZV versus NTHi-Mcat alone, indicating no immune interference. Starting from 1 month, no specific interval is required between RZV and NTHi-Mcat containing the same AS01-adjuvant system components in different quantities. |
format | Online Article Text |
id | pubmed-10078133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-100781332023-04-07 Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial Galgani, Ilaria Põder, Airi Jõgi, Rain Anttila, Veli-Jukka Milleri, Stefano Borobia, Alberto M. Launay, Odile Testa, Marco Casula, Daniela Grassano, Luca Tasciotti, Annaelisa Dozot, Marie Arora, Ashwani K. Hum Vaccin Immunother Novel Vaccines A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines containing the same AS01-adjuvant system could lead to immune interference. We compared administration of NTHi-Mcat following AS01-adjuvanted recombinant zoster vaccine (RZV) versus NTHi-Mcat alone. This phase 2a, open-label trial (NCT03894969) randomized healthy current or former smokers (50–80 years) without COPD to administration of NTHi-Mcat at 1, 3 or 6 months after RZV or to NTHi-Mcat alone (2-dose for both vaccines). Primary outcome was non-inferiority of the humoral immune response to NTHi-Mcat administered 1 month after RZV versus NTHi-Mcat alone, evaluated by specific antibody geometric mean concentration (GMC) ratio with 95% confidence intervals (CIs). The per-protocol set included 411 participants. Primary objective was met; lower limit of the 95%CI for the GMC ratio above 0.667 for all four vaccine antigens, 1 month after the second NTHi-Mcat dose. NTHi-Mcat induced similar immune response regardless of whether administered alone or 1, 3 or 6 months following RZV. Safety and reactogenicity profiles were acceptable; adverse event frequency was similar among study groups. Injection site pain was the most common symptom. No new safety concerns were identified. The study demonstrated non-inferiority of the immune response elicited by NTHi-Mcat administered sequentially to RZV versus NTHi-Mcat alone, indicating no immune interference. Starting from 1 month, no specific interval is required between RZV and NTHi-Mcat containing the same AS01-adjuvant system components in different quantities. Taylor & Francis 2023-03-28 /pmc/articles/PMC10078133/ /pubmed/36974988 http://dx.doi.org/10.1080/21645515.2023.2187194 Text en © 2023 GSK. Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Novel Vaccines Galgani, Ilaria Põder, Airi Jõgi, Rain Anttila, Veli-Jukka Milleri, Stefano Borobia, Alberto M. Launay, Odile Testa, Marco Casula, Daniela Grassano, Luca Tasciotti, Annaelisa Dozot, Marie Arora, Ashwani K. Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title | Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title_full | Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title_fullStr | Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title_full_unstemmed | Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title_short | Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial |
title_sort | immunogenicity and safety of the non-typable haemophilus influenzae–moraxella catarrhalis (nthi-mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: results from a randomized, phase 2a, non-inferiority trial |
topic | Novel Vaccines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078133/ https://www.ncbi.nlm.nih.gov/pubmed/36974988 http://dx.doi.org/10.1080/21645515.2023.2187194 |
work_keys_str_mv | AT galganiilaria immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT poderairi immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT jogirain immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT anttilavelijukka immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT milleristefano immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT borobiaalbertom immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT launayodile immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT testamarco immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT casuladaniela immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT grassanoluca immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT tasciottiannaelisa immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT dozotmarie immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial AT aroraashwanik immunogenicityandsafetyofthenontypablehaemophilusinfluenzaemoraxellacatarrhalisnthimcatvaccineadministeredfollowingtherecombinantzostervaccineversusadministrationaloneresultsfromarandomizedphase2anoninferioritytrial |